Published in Schizophr Res on October 08, 2008
Remission in schizophrenia: validity, frequency, predictors, and patients' perspective 5 years later. Dialogues Clin Neurosci (2010) 1.17
Health-related quality of life and overall life satisfaction in people with serious mental illness. Schizophr Res Treatment (2012) 0.81
Satisfaction with Life of Schizophrenia Outpatients and Their Caregivers: Differences between Patients with and without Self-Reported Sleep Complaints. Schizophr Res Treatment (2013) 0.75
Do patterns of change during treatment for panic disorder predict future panic symptoms? J Behav Ther Exp Psychiatry (2012) 0.75
Nonpharmacological interventions for ADHD: systematic review and meta-analyses of randomized controlled trials of dietary and psychological treatments. Am J Psychiatry (2013) 5.89
Sirt1 regulates aging and resistance to oxidative stress in the heart. Circ Res (2007) 5.23
Olanzapine long-acting injection: a 24-week, randomized, double-blind trial of maintenance treatment in patients with schizophrenia. Am J Psychiatry (2009) 3.56
Comorbid somatic illnesses in patients with severe mental disorders: clinical, policy, and research challenges. J Clin Psychiatry (2008) 2.86
Heroin-assisted treatment for opioid dependence: randomised controlled trial. Br J Psychiatry (2007) 2.25
Inhibition of endogenous thioredoxin in the heart increases oxidative stress and cardiac hypertrophy. J Clin Invest (2003) 2.19
Olanzapine versus placebo in the treatment of adolescents with bipolar mania. Am J Psychiatry (2007) 2.11
Predictors and clinical consequences of non-adherence with antipsychotic medication in the outpatient treatment of schizophrenia. Psychiatry Res (2010) 2.09
Inhalation treatment with glutathione in patients with cystic fibrosis. A randomized clinical trial. Am J Respir Crit Care Med (2013) 2.07
Isotopic evidence for glaciation during the Cretaceous supergreenhouse. Science (2008) 2.04
Hypoxia-inducible factor-1 (HIF-1) promotes its degradation by induction of HIF-alpha-prolyl-4-hydroxylases. Biochem J (2004) 1.90
Comparing and combining naltrexone and acamprosate in relapse prevention of alcoholism: a double-blind, placebo-controlled study. Arch Gen Psychiatry (2003) 1.73
Zebrafish embryos express an orthologue of HERG and are sensitive toward a range of QT-prolonging drugs inducing severe arrhythmia. Toxicol Appl Pharmacol (2003) 1.72
Prediction of remission as a combination of symptomatic and functional remission and adequate subjective well-being in 2960 patients with schizophrenia. J Clin Psychiatry (2006) 1.69
Evaluation of the Two-Way Communication Checklist as a clinical intervention. Results of a multinational, randomised controlled trial. Br J Psychiatry (2004) 1.61
A randomized double-blind study of atomoxetine versus placebo for attention-deficit/hyperactivity disorder symptoms in children with autism spectrum disorder. J Am Acad Child Adolesc Psychiatry (2012) 1.59
Physical and mental health in severe opioid-dependent patients within a randomized controlled maintenance treatment trial. Addiction (2011) 1.59
Efficacy and safety of lisdexamfetamine dimesylate and atomoxetine in the treatment of attention-deficit/hyperactivity disorder: a head-to-head, randomized, double-blind, phase IIIb study. CNS Drugs (2013) 1.58
Megacity emissions and lifetimes of nitrogen oxides probed from space. Science (2011) 1.54
Lats2 is a negative regulator of myocyte size in the heart. Circ Res (2008) 1.53
Early switch strategy in patients with major depressive disorder: a double-blind, randomized study. J Clin Psychopharmacol (2012) 1.52
Social and emotional impairment in children and adolescents with ADHD and the impact on quality of life. J Adolesc Health (2010) 1.50
Influence of atypical neuroleptics on executive functioning in patients with schizophrenia: a randomized, double-blind comparison of olanzapine vs. clozapine. Int J Neuropsychopharmacol (2005) 1.50
Cardiac-specific overexpression of AT1 receptor mutant lacking G alpha q/G alpha i coupling causes hypertrophy and bradycardia in transgenic mice. J Clin Invest (2005) 1.45
Early vs. conventional switching of antidepressants in patients with MDD and moderate to severe pain: a double-blind randomized study. J Affect Disord (2012) 1.42
[Early detection of psychosis in children and adolescents - have developmental particularities been sufficiently considered?]. Z Kinder Jugendpsychiatr Psychother (2011) 1.40
Non-stimulant medications in the treatment of ADHD. Eur Child Adolesc Psychiatry (2004) 1.38
Monolithic materials: Promises, challenges, achievements. Anal Chem (2006) 1.36
Monolithic capillary-based ion-selective electrodes. Anal Chem (2005) 1.36
An angiotensin II type 1 receptor mutant lacking epidermal growth factor receptor transactivation does not induce angiotensin II-mediated cardiac hypertrophy. Circ Res (2006) 1.30
Practitioner review: current best practice in the management of adverse events during treatment with ADHD medications in children and adolescents. J Child Psychol Psychiatry (2013) 1.29
Effects of clozapine and olanzapine on cytokine systems are closely linked to weight gain and drug-induced fever. Psychoneuroendocrinology (2008) 1.26
Memory and attention performance in psychiatric patients: lack of correspondence between clinician-rated and patient-rated functioning with neuropsychological test results. J Int Neuropsychol Soc (2004) 1.25
Glycogen synthase kinase-3alpha reduces cardiac growth and pressure overload-induced cardiac hypertrophy by inhibition of extracellular signal-regulated kinases. J Biol Chem (2007) 1.22
Association of subjective well-being, symptoms, and side effects with compliance after 12 months of treatment in schizophrenia. J Clin Psychiatry (2007) 1.21
Advantages and disadvantages of combination treatment with antipsychotics ECNP Consensus Meeting, March 2008, Nice. Eur Neuropsychopharmacol (2009) 1.19
H11 kinase prevents myocardial infarction by preemptive preconditioning of the heart. Circ Res (2005) 1.19
Current issues in schizophrenia: overview of patient acceptability, functioning capacity and quality of life. CNS Drugs (2004) 1.18
Remission in schizophrenia: validity, frequency, predictors, and patients' perspective 5 years later. Dialogues Clin Neurosci (2010) 1.17
Olanzapine versus ziprasidone: results of a 28-week double-blind study in patients with schizophrenia. Am J Psychiatry (2005) 1.16
Three-year antipsychotic effectiveness in the outpatient care of schizophrenia: observational versus randomized studies results. Eur Neuropsychopharmacol (2006) 1.15
Site-1 protease is required for cartilage development in zebrafish. Proc Natl Acad Sci U S A (2003) 1.15
Two-dimensional reversed-phase x ion-pair reversed-phase HPLC: an alternative approach to high-resolution peptide separation for shotgun proteome analysis. J Proteome Res (2007) 1.13
Orbital forcing of Cretaceous river discharge in tropical Africa and ocean response. Nature (2005) 1.13
Assertive community treatment as part of integrated care versus standard care: a 12-month trial in patients with first- and multiple-episode schizophrenia spectrum disorders treated with quetiapine immediate release (ACCESS trial). J Clin Psychiatry (2010) 1.11
H11 kinase is a novel mediator of myocardial hypertrophy in vivo. Circ Res (2002) 1.09
Pergolide versus levodopa monotherapy in early Parkinson's disease patients: The PELMOPET study. Mov Disord (2006) 1.09
Genome-wide association study in German patients with attention deficit/hyperactivity disorder. Am J Med Genet B Neuropsychiatr Genet (2011) 1.09
H11 kinase/heat shock protein 22 deletion impairs both nuclear and mitochondrial functions of STAT3 and accelerates the transition into heart failure on cardiac overload. Circulation (2011) 1.09
Absolute myoglobin quantitation in serum by combining two-dimensional liquid chromatography-electrospray ionization mass spectrometry and novel data analysis algorithms. J Proteome Res (2006) 1.07
Clozapine and olanzapine are associated with food craving and binge eating: results from a randomized double-blind study. J Clin Psychopharmacol (2007) 1.07
Intraprostatic fiducials for localization of the prostate gland: monitoring intermarker distances during radiation therapy to test for marker stability. Int J Radiat Oncol Biol Phys (2005) 1.06
Effectiveness of atomoxetine and quality of life in children with attention-deficit/hyperactivity disorder as perceived by patients, parents, and physicians in an open-label study. J Child Adolesc Psychopharmacol (2007) 1.06
Application of integrated transcriptomic, proteomic and metabolomic profiling for the delineation of mechanisms of drug induced cell stress. J Proteomics (2012) 1.06
Quality of life in obsessive-compulsive disorder before and after treatment. Compr Psychiatry (2005) 1.05
Statistical learning of peptide retention behavior in chromatographic separations: a new kernel-based approach for computational proteomics. BMC Bioinformatics (2007) 1.05
Impact of duration of untreated psychosis on pre-treatment, baseline, and outcome characteristics in an epidemiological first-episode psychosis cohort. J Psychiatr Res (2008) 1.05
Atomoxetine for the treatment of attention-deficit/hyperactivity disorder and oppositional defiant disorder. Pediatrics (2008) 1.05
Basic symptoms and the prediction of first-episode psychosis. Curr Pharm Des (2012) 1.05
Recovery in the outpatient setting: 36-month results from the Schizophrenia Outpatients Health Outcomes (SOHO) study. Schizophr Res (2008) 1.04
From nature versus nurture, via nature and nurture, to gene x environment interaction in mental disorders. Eur Child Adolesc Psychiatry (2009) 1.02
Assessing protein immunogenicity with a dendritic cell line-derived endolysosomal degradome. PLoS One (2011) 1.02
Separation, detection, and identification of peptides by ion-pair reversed-phase high-performance liquid chromatography-electrospray ionization mass spectrometry at high and low pH. J Chromatogr A (2005) 1.02
Hypothalamic-pituitary-adrenocortical axis activity: a target of pharmacological anticraving treatment? Biol Psychiatry (2006) 1.01
Depression, anxiety, and disturbed sleep in glaucoma. J Neuropsychiatry Clin Neurosci (2013) 1.00
Predictors of relapse in the year after hospital discharge among patients with schizophrenia. Psychiatr Serv (2012) 1.00
Subjective effects of antipsychotic drugs and their relevance for compliance and remission. Epidemiol Psichiatr Soc (2008) 1.00
G3139 and other CpG-containing immunostimulatory phosphorothioate oligodeoxynucleotides are potent suppressors of the growth of human tumor xenografts in nude mice. Oligonucleotides (2006) 0.99
The safety of olanzapine in adolescents with schizophrenia or bipolar I disorder: a pooled analysis of 4 clinical trials. J Clin Psychiatry (2009) 0.99
Improving treatment adherence in your patients with schizophrenia: the STAY initiative. Clin Drug Investig (2013) 0.99
Rationale and content of psychenet: the Hamburg Network for Mental Health. Eur Arch Psychiatry Clin Neurosci (2012) 0.99
Emotional well-being in children and adolescents treated with atomoxetine for attention-deficit/hyperactivity disorder: findings from a patient, parent and physician perspective using items from the pediatric adverse event rating scale (PAERS). Child Adolesc Psychiatry Ment Health (2008) 0.98
The near Babylonian speech confusion in early detection of psychosis. Schizophr Bull (2011) 0.98
SIMPATIQCO: a server-based software suite which facilitates monitoring the time course of LC-MS performance metrics on Orbitrap instruments. J Proteome Res (2012) 0.97
trans-Bis(perchlorato-κO)tetra-kis(1H-pyrazole-κN)copper(II). Acta Crystallogr Sect E Struct Rep Online (2008) 0.97
De novo peptide sequencing by tandem MS using complementary CID and electron transfer dissociation. Electrophoresis (2009) 0.95
The facial pattern of disgust, appetence, excited joy and relaxed joy: an improved facial EMG study. Scand J Psychol (2005) 0.95
Dissociative symptoms in alcohol-dependent patients: associations with childhood trauma and substance abuse characteristics. Compr Psychiatry (2007) 0.95
'A rose is a rose is a rose', but at-risk criteria differ. Psychopathology (2012) 0.94